Clinical data | |
---|---|
Other names | IMB-115 |
Drug class | Nociceptin receptor agonist |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H33N3O3 |
Molar mass | 435.568 g·mol−1 |
3D model ( JSmol) | |
| |
|
Sunobinop (developmental code name IMB-115) is a nociceptin receptor partial agonist and opioid receptor pan-antagonist. [1] As of March 2022, it is under investigation for the treatment of insomnia, [2] fibromyalgia, and overactive bladder. [1] [3]
Clinical data | |
---|---|
Other names | IMB-115 |
Drug class | Nociceptin receptor agonist |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H33N3O3 |
Molar mass | 435.568 g·mol−1 |
3D model ( JSmol) | |
| |
|
Sunobinop (developmental code name IMB-115) is a nociceptin receptor partial agonist and opioid receptor pan-antagonist. [1] As of March 2022, it is under investigation for the treatment of insomnia, [2] fibromyalgia, and overactive bladder. [1] [3]